Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib + Paclitaxel in NSCLC
NCT02503358Phase 1Completed
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jul 2016
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of selumetinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by OHSU Knight Cancer Institute. Primary endpoints: Incidence of grade 3 or higher treatment-related adverse event, Proportion of patients with treatment-related dose limiting toxicities at 21 days and 1 more. Started Jul 2016; status: completed.
02
Drugs
selumetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02503358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02503358.